Verici Dx Launches Groundbreaking Transplant Risk Assay

Verici Dx Plc (GB:VRCI) has released an update.

Verici Dx plc has successfully launched its Pre-Transplant Risk Assessment Assay, powered by technology licensed to Thermo Fisher Scientific, to aid clinicians in evaluating patient risk prior to organ transplant. The assay, which assesses the risk of early acute rejection by analyzing a patient’s unique gene profile, represents a significant advancement in personalized transplant diagnostics. This collaboration underscores Verici Dx’s commitment to improving patient outcomes through innovative diagnostic solutions.

For further insights into GB:VRCI stock, check out TipRanks’ Stock Analysis page.